Bayer strengthens research and development pharmaceutical pipeline is well filled, with 50 projects currently in phases I to III of clinical testing

摘要

THE Bayer Group is to further expand its research and development activities despite the current financial and economic crisis. "The task now is to set the right course. Only through innovation can our company generate the growth that is essential to safeguard its sustained success," said Werner Wenning, Chairman of the Board of Management of Bayer AG. In 2008 the company's research and development budget is at around EUR 2.8 billion. "This represents the biggest R&D budget in Germany in the chemical and pharmaceutical sector - and amounts to about five percent of all research and development spending by German industry as a whole," explained Wenning. Bayer will continue in the future to commit itself to strong research and development.